Platelet Receptor Blocking Agents
Platelets play a fundamental role in hemostasis and thrombosis. Blocking platelet activation and aggregation is a primary task to prevent and limit thrombosis. We developed a murine monoclonal antibody, 7E3, directed against human αIIbβ3, which is able to inhibit platelet aggregation. Abciximab, the chimeric Fab fragment of 7E3, has been demonstrated to reduce mortality and thrombotic complications after percutaneous coronary interventions. ~ 2,000,000 patients have been treated with abciximab worldwide.
Other antibodies, directed against human and murine integrins, are currently studied in the laboratory.